Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer

Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?

(2019) P Hofman et al.   ANNALS OF ONCOLOGY

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer

(2018) Ming Li et al.   BMC CANCER

The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer

(2018) André Steven et al.   Breast Care

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers

(2018) Séverine Guiu et al.   BRITISH JOURNAL OF CANCER

Expression de PD-L1 et inhibiteurs de la voie PD-1/PD-L1 dans le cancer du sein

(2018) Audrey Monneur et al.   BULLETIN DU CANCER

Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC

(2018) B. Melosky et al.   CANCER TREATMENT REVIEWS

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

(2018) Massimo Cristofanilli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Targeting Immune Checkpoints in Cancer Therapy

(2017) Suzanne L. Topalian   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors

(2017) Dorothea Sonja Schott et al.   Oncotarget

PD-1/PD-L1 Pathway in Breast Cancer

(2017) Florian Schütz et al.   Oncology Research and Treatment

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

(2016) Francesco Passiglia et al.   Oncotarget

Targeting the host immune system

(2016) Shaheenah Dawood et al.   Current Opinion in Supportive and Palliative Care

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

(2015) H. R. Ali et al.   ANNALS OF ONCOLOGY

Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer

(2015) Francois-Clement Bidard et al.   JOURNAL OF CLINICAL ONCOLOGY

Frequent expression of PD-L1 on circulating breast cancer cells

(2015) Martine Mazel et al.   Molecular Oncology

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

(2014) François-Clément Bidard et al.   LANCET ONCOLOGY

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

(2014) L.B. Jilaveanu et al.   Journal of Cancer

Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?

(2013) K. Pantel et al.   CANCER RESEARCH

Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines

(2013) A Q Butt et al.   ONCOGENE

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

(2011) J.- Y. Pierga et al.   ANNALS OF ONCOLOGY